[
  {
    "ts": null,
    "headline": "Healthcare Earnings Are Coming. 4 Big Questions for CVS, Humana, Merck, UnitedHealth, and More.",
    "summary": "The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here are five problems they need to address.",
    "url": "https://finnhub.io/api/news?id=effbd36456b93069516cc1612f178c1d9cc51814939ac44278d6997b46475248",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753720800,
      "headline": "Healthcare Earnings Are Coming. 4 Big Questions for CVS, Humana, Merck, UnitedHealth, and More.",
      "id": 136108043,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here are five problems they need to address.",
      "url": "https://finnhub.io/api/news?id=effbd36456b93069516cc1612f178c1d9cc51814939ac44278d6997b46475248"
    }
  },
  {
    "ts": null,
    "headline": "Magnificent 7 Diverge As Peak Earnings Season Puts Spotlight On Big Tech",
    "summary": "Peak earnings season for Q2 2025 begins this week. So far 34% of companies from the S&P 500 index have reported, and the early results bode well for the rest of the season. Read more here...",
    "url": "https://finnhub.io/api/news?id=d3fc3c5e315c1cffd8faa7f6424fbbd59419cb37287f073c7dbb9905af254e0c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753718700,
      "headline": "Magnificent 7 Diverge As Peak Earnings Season Puts Spotlight On Big Tech",
      "id": 136109386,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/500552643/image_500552643.jpg?io=getty-c-w1536",
      "related": "CVS",
      "source": "SeekingAlpha",
      "summary": "Peak earnings season for Q2 2025 begins this week. So far 34% of companies from the S&P 500 index have reported, and the early results bode well for the rest of the season. Read more here...",
      "url": "https://finnhub.io/api/news?id=d3fc3c5e315c1cffd8faa7f6424fbbd59419cb37287f073c7dbb9905af254e0c"
    }
  },
  {
    "ts": null,
    "headline": "Will Exome and Genome Growth Boost WGS' Q2 Earnings?",
    "summary": "GeneDx is likely to have experienced a Q2 lift, backed by strong Exome and genome test volumes, new indications and strategic tech moves.",
    "url": "https://finnhub.io/api/news?id=7b2f7f6f0fc029c4ac003542ce412cf6de99025e6cb03e0f881d34cf02b78fd2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753709160,
      "headline": "Will Exome and Genome Growth Boost WGS' Q2 Earnings?",
      "id": 136108553,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "GeneDx is likely to have experienced a Q2 lift, backed by strong Exome and genome test volumes, new indications and strategic tech moves.",
      "url": "https://finnhub.io/api/news?id=7b2f7f6f0fc029c4ac003542ce412cf6de99025e6cb03e0f881d34cf02b78fd2"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk faces 'show me' moment to boost Wegovy growth after US copycat ban",
    "summary": "LONDON (Reuters) -A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will need to show more robust growth in the months ahead to bolster market confidence, investors and analysts say.  New Wegovy prescriptions have increased by about 33% since May 22, when a U.S. Food and Drug Administration ban on so-called compounded versions of Wegovy took effect, amounting to 181,200 in the week ended July 18, according to data from IQVIA that was shared with Reuters by industry analysts.  Total Wegovy prescriptions have also increased, narrowing the lead for Eli Lilly and Co's Zepbound.",
    "url": "https://finnhub.io/api/news?id=f3be02f95a064a660c79eded7cfe8ca85f0d3f7ee21a1001a4347b7b33ca7532",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753697057,
      "headline": "Novo Nordisk faces 'show me' moment to boost Wegovy growth after US copycat ban",
      "id": 136107936,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "LONDON (Reuters) -A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will need to show more robust growth in the months ahead to bolster market confidence, investors and analysts say.  New Wegovy prescriptions have increased by about 33% since May 22, when a U.S. Food and Drug Administration ban on so-called compounded versions of Wegovy took effect, amounting to 181,200 in the week ended July 18, according to data from IQVIA that was shared with Reuters by industry analysts.  Total Wegovy prescriptions have also increased, narrowing the lead for Eli Lilly and Co's Zepbound.",
      "url": "https://finnhub.io/api/news?id=f3be02f95a064a660c79eded7cfe8ca85f0d3f7ee21a1001a4347b7b33ca7532"
    }
  }
]